Silverback Therapeutics (SBTX) Competitors $17.50 -0.15 (-0.85%) As of 08/8/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock SBTX vs. MENS, CALT, ZYME, MBX, NLTX, AVTE, CYBN, BIOA, VIRI, and WHWKShould you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Jyong Biotech (MENS), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Aerovate Therapeutics (AVTE), Cybin (CYBN), BioAge Labs (BIOA), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). Silverback Therapeutics vs. Its Competitors Jyong Biotech Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Neoleukin Therapeutics Aerovate Therapeutics Cybin BioAge Labs Virios Therapeutics Whitehawk Therapeutics Silverback Therapeutics (NASDAQ:SBTX) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends. Is SBTX or MENS more profitable? Jyong Biotech's return on equity of 0.00% beat Silverback Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silverback TherapeuticsN/A -29.62% -28.20% Jyong Biotech N/A N/A N/A Does the media refer more to SBTX or MENS? In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score. Company Overall Sentiment Silverback Therapeutics Neutral Jyong Biotech Neutral Do insiders and institutionals hold more shares of SBTX or MENS? 74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, SBTX or MENS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilverback TherapeuticsN/AN/A-$89.48M-$2.42-7.23Jyong BiotechN/AN/AN/AN/AN/A SummarySilverback Therapeutics and Jyong Biotech tied by winning 2 of the 4 factors compared between the two stocks. Get Silverback Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBTX vs. The Competition Export to ExcelMetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$631.02M$793.17M$5.47B$9.71BDividend YieldN/A4.84%4.59%4.12%P/E Ratio-7.231.1830.1024.70Price / SalesN/A25.58458.36100.90Price / CashN/A19.5624.8428.01Price / Book2.366.548.525.76Net Income-$89.48M-$4.11M$3.27B$267.05M7 Day Performance1.86%120.04%4.65%3.13%1 Month Performance-2.67%0.44%0.96%1.27%1 Year Performance60.85%22.82%36.43%22.83% Silverback Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBTXSilverback TherapeuticsN/A$17.50-0.8%N/A+60.8%$631.02MN/A-7.2383High Trading VolumeMENSJyong BiotechN/A$24.52+4.5%N/AN/A$1.86BN/A0.0031CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks3.196 of 5 stars$12.37-1.8%$21.00+69.8%+18.8%$866.09M$93.38M-8.29460News CoverageEarnings ReportAnalyst RevisionMBXMBX Biosciences2.5375 of 5 stars$12.04-4.0%$37.63+212.6%N/A$407.94MN/A0.0036Gap UpNLTXNeoleukin TherapeuticsN/A$21.72-0.3%N/A-40.4%$204.13MN/A-6.9890Gap UpAVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.3%$199.71MN/A-2.3020News CoverageHigh Trading VolumeCYBNCybin2.8373 of 5 stars$7.54-1.9%$85.00+1,028.1%N/A$177.87MN/A-1.7250Positive NewsBIOABioAge LabsN/A$4.42flatN/AN/A$158.46MN/A0.00N/AEarnings ReportAnalyst RevisionVIRIVirios Therapeutics0.1101 of 5 stars$4.86+0.2%$5.00+2.9%+2,702.3%$93.59MN/A-18.005WHWKWhitehawk TherapeuticsN/A$1.79+1.7%N/AN/A$84.33M$27.78M11.1940News CoverageEarnings ReportAnalyst Downgrade Related Companies and Tools Related Companies MENS Alternatives CALT Alternatives ZYME Alternatives MBX Alternatives NLTX Alternatives AVTE Alternatives CYBN Alternatives BIOA Alternatives VIRI Alternatives WHWK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBTX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale